Conference Call with Alembic Pharmaceuticals Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Alembic Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Net Sales increased by 17% to Rs.1770 crore EBITDA up by 9% to Rs. 286 crore EBITDA Margin at 16% of Sales Profit Before Tax up by 5% to Rs.192 crore Net Profit at Rs.157 crore FY25 Financial Highlights: Revenue from operations stood at 6672 crore for FY25 compared to 6228 crore for FY24 Net profit stands at 583 crore for FY25 compared to compared to 615 crore for FY24 Shaunak Amin, MD, Alembic Pharmaceuticals, said, “India-Branded Business displayed improved performance, backed by Specialty therapies. While the Animal Health division continued to outperform through a strong portfolio of trusted brands. By deepening our engagement with healthcare professionals and expanding our product pipeline, we have laid a solid foundation for strong, consistent growth, going forward. Our Ex-US business delivered a strong growth of 43% across all markets whereas the US business grew by 20% during the quarter.” Result PDF